This website is intended for healthcare professionals

Progressive multifocal leukoencephalopathy

Natalizumab for the treatment of highly active MS: risks and benefits

Natalizumab is a DMT that is used in highly active RRMS, which has a high efficacy of 70% for reducing relapses and sustaining disease progression. It is given by intravenous infusion every 4 weeks,...

Why choose Journal of Prescribing Practice?

Journal of Prescribing Practice shares the latest clinical expertise and professional guidance for non-medical prescribers. Our goal is to provide the knowledge to help you prescribe more efficiently and effectively.

What's included

  • Evidence-based best practice

  • Drug updates

  • Pharmacology information

  • Calculation skills

Subscriptions start:

From £16.25 GBP